Published in Br J Haematol on June 01, 1998
Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity. J Leukoc Biol (2011) 1.41
Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut (2003) 1.35
P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother (2004) 1.06
HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology (2007) 0.96
Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome. Biol Blood Marrow Transplant (2011) 0.92
Multidrug transporter activity in lymphocytes. Br J Pharmacol (2004) 0.88
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res Hum Retroviruses (2010) 0.80
The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection. Infect Immun (2015) 0.78
Haemonchus contortus P-glycoproteins interact with host eosinophil granules: a novel insight into the role of ABC transporters in host-parasite interaction. PLoS One (2014) 0.78
New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells. Antimicrob Agents Chemother (2015) 0.75
Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy. Bioorg Med Chem Lett (2012) 0.75
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet (2000) 3.18
Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 1.56
TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol (2008) 1.32
Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology (2000) 1.23
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol (2007) 1.20
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer (1997) 1.19
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (2003) 1.16
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents (2010) 1.15
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest (2000) 1.15
Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med (1990) 1.14
Cyclosporin blood levels do correlate with clinical complications. Lancet (1984) 1.07
Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis (2007) 1.06
Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res (1998) 1.01
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol (2000) 1.00
In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol (1988) 0.99
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer (2004) 0.99
Gene trap integrations expressed in the developing heart: insertion site affects splicing of the PT1-ATG vector. Dev Dyn (1998) 0.99
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology (2000) 0.98
Hematopoietic stem cells. Biomed Pharmacother (2001) 0.97
Breath acetone-aspects of normal physiology related to age and gender as determined in a PTR-MS study. J Breath Res (2009) 0.96
Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol (1987) 0.96
Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol (1989) 0.93
Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol (1992) 0.93
Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann Hematol (2001) 0.93
Spontaneous remission in a secondary acute myelogenous leukaemia following invasive pulmonary aspergillosis. Ann Hematol (2001) 0.93
LST1: a gene with extensive alternative splicing and immunomodulatory function. J Immunol (2000) 0.92
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol (1991) 0.90
Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood (1984) 0.90
In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp Hematol (1997) 0.90
Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Ann Hematol (1991) 0.89
Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol (2003) 0.89
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J Infect Dis (2000) 0.87
Susceptibility of human retinal pigment epithelial cells to different viruses. Graefes Arch Clin Exp Ophthalmol (1996) 0.85
Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res (1985) 0.85
Exposure to retinoic acid before or after the onset of somitogenesis reveals separate effects on rhombomeric segmentation and 3' HoxB gene expression domains. Development (1994) 0.85
Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res (2002) 0.84
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res (2003) 0.84
Quality of life during chemotherapy in lung cancer patients: results across different treatment lines. Br J Cancer (2013) 0.83
Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2006) 0.82
Feasibility of a multdisciplinary lung cancer videoconference between a peripheral hospital and a comprehensive cancer centre. Oncology (2013) 0.81
Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res (1985) 0.81
Vascular endothelial growth factor in serum and in the follicular fluid of patients undergoing hormonal stimulation for in-vitro fertilization. Hum Reprod (1998) 0.81
Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. Eur J Cancer (1991) 0.81
Circulating endothelial cells after transplantation. Lancet (2001) 0.81
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol (2010) 0.80
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. Cancer Res (1997) 0.80
The relationship of HNK-1 (Leu 7) and VEP13 antigens on human cells mediating natural killing. Clin Exp Immunol (1984) 0.80
The kinase inhibitor imatinib--an immunosuppressive drug? Curr Cancer Drug Targets (2007) 0.80
Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke (2001) 0.79
Minimal interferon-alpha doses for hairy cell leukemia. Blood (1990) 0.79
A biological approach to optimize interferon treatment in hairy cell leukemia. Immunobiology (1986) 0.79
Large granular lymphocytes: morphological studies. Eur J Immunol (1982) 0.79
Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie (2004) 0.79
Bone marrow may be the preferable graft source in recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors. Bone Marrow Transplant (2011) 0.78
Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL). Leuk Res (1999) 0.78
Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses (2005) 0.78
Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Eur J Haematol (2001) 0.78
Treatment of hairy-cell leukemia with recombinant alpha 2-interferon. Eur J Cancer Clin Oncol (1986) 0.78
Macrophage infiltration in non-Hodgkin's lymphomas: a quantitative in situ study. Immunobiology (1986) 0.78
Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. J Interferon Res (1987) 0.78
Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology (1987) 0.78
Recombinant alpha 2 interferon for induction and maintenance of remission in hairy cell leukaemia. Br J Haematol (1985) 0.78
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status. Int J Cancer (1988) 0.78
T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. Int J Lab Hematol (2008) 0.77
Current treatment concepts of Philadelphia-negative MPN. Curr Cancer Drug Targets (2011) 0.77
Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. Immunobiology (1990) 0.77
Current and future strategies to block tumor angiogenesis, invasion, and metastasis. World J Urol (1996) 0.77
Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment with Nocardia rubra cell wall skeleton and bacille-Calmette-Guerin. Urol Res (1997) 0.77
Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol (1995) 0.77
Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst (1993) 0.77
Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J Clin Pathol (2004) 0.77
Abnormal expansions of granular lymphocytes: reactive lymphocytosis or chronic leukemia? Case report and literature review. Blut (1986) 0.77
[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr (2004) 0.77
Expression of c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia. Cytokines Mol Ther (1995) 0.77
Optimal timing for the collection and in vitro expansion of cytotoxic CD56(+) lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation. J Hematother Stem Cell Res (2001) 0.76
Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol (2003) 0.76
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol (2013) 0.76
[Palliative immunotherapy of cancer]. Ther Umsch (2001) 0.76
Platelets and VEGF blood levels in cancer patients. Br J Cancer (1999) 0.76
Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol (1993) 0.76
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (2000) 0.76
Space flight and growth factors. Lancet (1999) 0.76
Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes. Biol Blood Marrow Transplant (2004) 0.76
Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab. Br J Dermatol (2008) 0.75
IgM myeloma: more on a rare entity. Br J Haematol (2008) 0.75
Vascular endothelial growth factor platelet counts and renal cancer. Lancet (1999) 0.75
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res (1989) 0.75
Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Invest (2001) 0.75
Correspondence re: P. Salven et al., leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res., 5: 487-91, 1999. Clin Cancer Res (1999) 0.75
Dose related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut (1987) 0.75
Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol (1995) 0.75
[Short survey of the state of hospital hygiene in Hungary]. Z Gesamte Hyg (1984) 0.75